<DOC>
	<DOCNO>NCT01039428</DOCNO>
	<brief_summary>This study evaluate efficacy safety HS219 , chitosan-loaded chewing gum , give three time day 3 week hemodialysis ( HD ) patient hyperphosphatemia whose serum inorganic phosphorus well control calcium carbonate sevelamer hydrogen chloride .</brief_summary>
	<brief_title>A Study HS219 Chronic Kidney Disease Patients Hemodialysis With Hyperphosphatemia</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Hyperphosphatemia</mesh_term>
	<criteria>Written inform consent give Able comply study procedure medication On stable HD regimen ( least 3 x per week ) ≥ 3 month Subject receive calcium carbonate sevelamer hydrochloride phosphate binder screening , must stable regimen ( dose medication ) least 1 month A mean serum inorganic phosphorous previous 3 test : &gt; 5.5 mg/dL &lt; 9.0 mg/dL Removal rate blood urea nitrogen ( BUN ) ≥ 60 % Rate salivary flow Saxon test ≥ 1 g/2 min Blood purification therapy HD Current clinically significant intestinal motility disorder Possible parathyroid intervention study period History malignancy severe cardiovascular disorder heart disease , angina , congest heart failure , valve stenosis , atrial fibrillation arrhythmia History allergy active ingredient Receipt investigational drug within 30 day inform consent</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>hyperphosphatemia</keyword>
	<keyword>hemodialysis</keyword>
	<keyword>chitosan</keyword>
</DOC>